Physician profile
Amy E Upton
NPI 1063719573
$1,901.96
in general payments reported to CMS, 2019-2025
21 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $388 · 2022: $533 · 2023: $359 · 2024: $492 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Travel and Lodging: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.51 |
| Travel and Lodging | $104.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $413.44 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Optinose US, INC. | $251.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.98 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $176.91 | 2022-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $148.43 | 2023-2024 | |
| Glaxosmithkline, LLC. | $137.64 | 2021-2022 | |
| Shockwave Medical, INC | $104.75 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $76.59 | 2021-2024 | Zepbound, Jardiance |
| Amgen INC. | $49.21 | 2021-2022 | |
| Biogen, INC. | $46.11 | 2021 | |
| Revance Therapeutics, INC. | $45.18 | 2025 | Daxxify |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.63 | 2022 | |
| Galderma Laboratories, L.P. | $27.42 | 2021-2022 | |
| Novo Nordisk INC | $25.49 | 2021-2023 | Ozempic |
| Arbor Pharmaceuticals, INC. | $25.45 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19.88 | 2021 | |
| Pfizer INC. | $17.82 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $16.47 | 2021 | |
| Gilead Sciences, INC. | $16.23 | 2021 | |
| Exact Sciences Corporation | $15.03 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $5.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Upton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.